

Hyung Joon Yim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5284667/publications.pdf>

Version: 2024-02-01

69
papers

2,665
citations

331670

21
h-index

189892

50
g-index

69
all docs

69
docs citations

69
times ranked

2703
citing authors

#	ARTICLE	IF	CITATIONS
1	Besifovir therapy improves hepatic histology and reduces covalently closed circular DNA in chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 378-386.	2.8	4
2	Determinants of reâ€compensation in patients with hepatitis B virusâ€related decompensated cirrhosis starting antiviral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 83-96.	3.7	13
3	Telbivudine Plus Adefovir Versus Lamivudine Plus Adefovir for Lamivudine-Resistant Chronic Hepatitis B: TeSLA Randomized Trial. <i>Hepatitis Monthly</i> , 2022, 21, .	0.2	0
4	Clinical Effect of Hepatitis B Virus on COVID-19 Infected Patients: A Nationwide Population-Based Study Using the Health Insurance Review & Assessment Service Database. <i>Journal of Korean Medical Science</i> , 2022, 37, e29.	2.5	16
5	FIB-4 index and liver fibrosis are risk factors for long-term outcomes in atrial fibrillation-related stroke. <i>Clinical Neurology and Neurosurgery</i> , 2022, 217, 107235.	1.4	1
6	Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy. <i>Journal of Hepatology</i> , 2022, 77, 967-977.	3.7	25
7	Improved anti-fibrotic effects by combined treatments of simvastatin and NS-398 in experimental liver fibrosis models. <i>Korean Journal of Internal Medicine</i> , 2022, 37, 745-756.	1.7	6
8	Maintaining Antiviral Efficacy after Switching to Generic Entecavir 1 mg for Antiviral-resistant Chronic Hepatitis B. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2021, 77, 22-29.	0.4	2
9	Primary prophylaxis of gastric variceal bleeding: endoscopic obturation, radiologic intervention, or observation?. <i>Hepatology International</i> , 2021, 15, 934-945.	4.2	11
10	Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. <i>Gut and Liver</i> , 2021, 15, 284-294.	2.9	33
11	Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2021, 15, 420-429.	2.9	11
12	Partial Virological Response after 2 Years of Entecavir Therapy Increases the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Associated Cirrhosis. <i>Gut and Liver</i> , 2021, 15, 430-439.	2.9	5
13	Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2021, 21, 258.	2.0	14
14	Direct Bilirubin Is More Valuable than Total Bilirubin for Predicting Prognosis in Patients with Liver Cirrhosis. <i>Gut and Liver</i> , 2021, 15, 599-605.	2.9	18
15	<i>Lens culinaris</i> agglutinin-reactive fraction of alpha-fetoprotein improves diagnostic accuracy for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2021, 27, 4687-4696.	3.3	6
16	A case report of a patient presented with skin ulcer after treatment of lenvatinib. <i>Journal of Liver Cancer</i> , 2021, 21, 194-198.	1.1	1
17	Addition of liver stiffness enhances the predictive accuracy of the PAGEâ€B model for hepatitis Bâ€related hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 919-927.	3.7	7
18	Microbiome as a potential diagnostic and predictive biomarker in severe alcoholic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 540-551.	3.7	22

#	ARTICLE	IF	CITATIONS
19	Prognosis predictability of serum and urine renal markers in patients with decompensated cirrhosis: A multicentre prospective study. <i>Liver International</i> , 2020, 40, 3083-3092.	3.9	11
20	Tenofovir-based combination therapy or monotherapy for multidrug-resistant chronic hepatitis B: Long-term data from a multicenter cohort study. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1306-1318.	2.0	1
21	Predictive score for hepatocellular carcinoma after hepatitis B e antigen loss in patients treated with entecavir or tenofovir. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1052-1060.	2.0	7
22	Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 196-204.	3.7	43
23	Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. <i>Gut</i> , 2020, 69, 2214-2222.	12.1	20
24	Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 411-429.	8.9	66
25	Evaluation of Treatment Response after Endoscopic Variceal Obturation with Abdominal Computed Tomography. <i>Gut and Liver</i> , 2020, 14, 117-124.	2.9	5
26	First-line Helicobacter pylori Eradication Rate of the 10-day Hybrid Therapy. <i>The Korean Journal of Helicobacter and Upper Gastrointestinal Research</i> , 2020, 20, 300-305.	0.4	0
27	Differential Impact of Serum 25-Hydroxyvitamin D3 Levels on the Prognosis of Patients with Liver Cirrhosis According to MELD and Child-Pugh Scores. <i>Journal of Korean Medical Science</i> , 2020, 35, e129.	2.5	4
28	Assessment and prediction of acute kidney injury in patients with decompensated cirrhosis with serum cystatin C and urine N-acetylgalactosaminidase. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 234-240.	2.8	17
29	Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). <i>Oncology</i> , 2019, 8, 1615817.	4.6	85
30	Long-term Outcomes of Antiviral Therapy in Patients With Advanced Chronic HBV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2811-2813.e1.	4.4	9
31	Prognostic assessment using a new substaging system for Barcelona clinic liver cancer stage C hepatocellular carcinoma: A nationwide study. <i>Liver International</i> , 2019, 39, 1109-1119.	3.9	6
32	Prediction of the varices needing treatment with non-invasive tests in patients with compensated advanced chronic liver disease. <i>Liver International</i> , 2019, 39, 1071-1079.	3.9	33
33	Long-term Prognosis of Acute-on-Chronic Liver Failure Survivors. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 134-141.	2.2	21
34	Sorafenib-induced Pancreatic Pseudocyst in a Patient with Advanced Hepatocellular Carcinoma: a Rare Adverse Event. <i>Journal of Liver Cancer</i> , 2019, 19, 154-158.	1.1	0
35	How can we improve the performance of Model for End-stage Liver Disease sodium score in patients with hepatitis B virus-related decompensated liver cirrhosis commencing antiviral treatment?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1641-1648.	2.8	7
36	P123 The effect of necrosis inhibition on acute DSS colitis model of inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S154-S155.	1.3	0

#	ARTICLE	IF	CITATIONS
37	Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 503-510.	2.8	24
38	Serum cystatin C level: An excellent predictor of mortality in patients with cirrhotic ascites. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 910-917.	2.8	19
39	Clinical usefulness of psoas muscle thickness for the diagnosis of sarcopenia in patients with liver cirrhosis. <i>Clinical and Molecular Hepatology</i> , 2018, 24, 319-330.	8.9	88
40	Risk Factors for Dropout From the Liver Transplant Waiting List of Hepatocellular Carcinoma Patients Under Locoregional Treatment. <i>Transplantation Proceedings</i> , 2018, 50, 3521-3526.	0.6	4
41	Switching to tenofovir vs continuing entecavir for hepatitis B virus with partial virologic response to entecavir: a randomized controlled trial. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1321-1330.	2.0	17
42	Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 469-478.	2.3	88
43	Rapid Alanine Aminotransferase Normalization with Entecavir and Hepatocellular Carcinoma in Hepatitis B Virus-Associated Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2017, 62, 808-816.	2.3	9
44	Endoscopic biliary stent insertion through specialized duodenal stent for combined malignant biliary and duodenal obstruction facilitated by stent or PTBD guidance. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1258-1262.	1.5	7
45	Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study. <i>Gut and Liver</i> , 2017, 11, 129-135.	2.9	3
46	A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. <i>Hepatology International</i> , 2016, 10, 947-955.	4.2	17
47	Improvement of liver function and noninvasive fibrosis markers in hepatitis B virus-associated cirrhosis: 2 years of entecavir treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1775-1781.	2.8	15
48	Current management of hepatocellular carcinoma: An Eastern perspective. <i>World Journal of Gastroenterology</i> , 2015, 21, 3826.	3.3	48
49	A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. <i>Journal of Gastroenterology</i> , 2015, 50, 445-454.	5.1	121
50	Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies. <i>World Journal of Gastroenterology</i> , 2015, 21, 10874.	3.3	14
51	Comparison of Lamivudine Plus Adefovir Therapy Versus Entecavir With or Without Adefovir Therapy for Adefovir-resistant Chronic Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 889-895.	2.2	8
52	Systemic Cytotoxic Chemotherapy of Patients With Advanced Hepatocellular Carcinoma in the Era of Sorafenib Nonavailability. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, e22-e29.	2.2	18
53	Adefovir and Lamivudine Combination Therapy in Patients with Entecavir-Resistant Chronic Hepatitis B: Antiviral Responses and Evolution of Mutations. <i>Intervirology</i> , 2014, 57, 239-247.	2.8	5
54	Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. <i>Hepatology</i> , 2014, 60, 954-963.	7.3	169

#	ARTICLE	IF	CITATIONS
55	Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (<scp>ACE</scp> study): a 2-year follow-up randomized controlled trial. <i>Liver International</i> , 2013, 33, 244-254.	3.9	21
56	Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 195.	8.9	27
57	Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis. <i>Liver International</i> , 2012, 32, 656-664.	3.9	32
58	Comparison of Clevudine and Entecavir for Treatment-naïve Patients With Chronic Hepatitis B Virus Infection. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 893-899.	2.2	19
59	Serum aminotransferase levels instead of etiology affects the accuracy of transient elastography in chronic viral hepatitis patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 492-500.	2.8	26
60	Healthy range for serum ALT and the clinical significance of "unhealthy" normal ALT levels in the Korean population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 292-299.	2.8	49
61	Application of the HALF index obviates the need for liver biopsy in half of all patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 987-995.	2.8	15
62	A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 373-382.	2.3	55
63	Terlipressin-induced hyponatremic seizure. <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 501-504.	1.5	480
64	Durability of Antiviral Response in HBeAg-Positive Chronic Hepatitis B Patients Who Maintained Virologic Response for One Year After Lamivudine Discontinuation. <i>Digestive Diseases and Sciences</i> , 2009, 54, 1572-1577.	2.3	10
65	A Case of Portopulmonary Hypertension Associated with Primary Biliary Cirrhosis. <i>Tuberculosis and Respiratory Diseases</i> , 2007, 62, 421.	1.8	0
66	Levels of Hepatitis B Virus (HBV) Replication During the Nonreplicative Phase: HBV Quantification by Real-Time PCR in Korea. <i>Digestive Diseases and Sciences</i> , 2007, 52, 2403-2409.	2.3	7
67	Natural History of Chronic Hepatitis B Virus Infection: What We Knew in 1981 and What We Know in 2005. <i>Hepatology</i> , 2006, 43, S173-S181.	7.3	457
68	Evolution of multi-drug resistant hepatitis B virus during sequential therapy. <i>Hepatology</i> , 2006, 44, 703-712.	7.3	238
69	Factors related to post-treatment relapse in chronic hepatitis B patients who lost HBeAg after lamivudine therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 1838-1842.	2.8	25